Chardan Capital Markets

Arbutus Biopharma Corp (NASDAQ: ABUS) reported additional data from the Phase II trial of ARB-1467, its RNAi drug for the treatment of chronic hepatitis B virus (HBV). Citing safety concerns related to ARB-1467, Chardan Capital Markets’ Madhu Kumar downgraded the rating on the company from...

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has underperformed Amgen, Inc. (NASDAQ: AMGN) as well as the NBI year-to-date in 2016, while a key threat, in the form of Ophthotech Corp (NASDAQ: OPHT)'s Fovista, has been eliminated. Chardan Capital’s Gbola Amusa upgraded the rating on Regeneron...

On December 12, Ophthotech Corp (NASDAQ: OPHT) announced that its Phase III trials, OPH1002 and OPH1003, revealed negative results in wet age-related macular degeneration (AMD). Chardan Capital’s Gbola Amusa downgraded the rating on the company from Buy to Neutral, while lowering the...

Eyegate Pharmaceuticals Inc (NASDAQ: EYEG) reported additional encouraging results from the Phase 1b/2a clinical study of its lead product, EGP-437, in patients who have undergone cataract surgery. Terming the lead compound as “promising,” Chardan Capital Markets' Keay Nakae...

Vuzix Corporation (NASDAQ: VUZI) has recently raised $14 million in an equity offering. The company is heading into the CES (Consumer Electronics Show) with a robust balance sheet as well as “a broad and expanding product line,” Chardan Capital Markets’ James McIlree said in a...

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has announced the discontinuation of all its clinical RNAi programs, citing safety issues. This development could boost Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)'s market share in both HBV (hepatitis B virus) RNAi and (alpha-1 antitrypsin), Chardan...

Channel checks indicate strong growth for Wageworks Inc (NYSE: WAGE) over the next couple of years from multiple sources, Chardan Capital Markets’ Steven Wardell said in a report. He initiated coverage on the company with a Buy rating and a price target of $86. WageWorks’ growth over...

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) announced it was discontinuing all its clinical RNAi programs. All these programs use the dynamic polyconjugate (DPC) platform in the EX-1 delivery vehicle. Chardan Capital’s Madhu Kumar downgraded the rating on the company to Neutral, while...

Shares of Amicus Therapeutics, Inc. (NASDAQ: FOLD) plunged more than 22 percent on news that the FDA seeks a pivotal "cross-over" study of Galafold (migalastat) in treatment-naive Fabry disease patients with gastrointestinal (GI) symptoms to approve the drug. FDA Requests Additional...

Recent channel checks indicate robust growth for Teladoc Inc (NYSE: TDOC) over the next couple of years, backed by strong demand for telehealth, Chardan Capital Markets’ Steven Wardel said in a report. He initiated coverage of the company with a Buy rating and a price target of $24....

Clovis Oncology Inc’s (NASDAQ: CLVS) lead asset rucaparib has a poor risk-benefit profile. The candidate’s lack of efficacy over current treatments and safety signals represent “considerable risks” ahead of its PDUFA in February next year, Chardan Capital Markets’...

Chardan Capital’s Gbola Amusa believes Novartis AG (ADR) (NYSE: NVS) has the “potential for excess shareholder returns over the long-term by generating shared value for society through performance on 1) disruptive or sustainable innovation, 2) access to medicines initiatives, and/or 3)...

Taking a look back at last week's Benzinga Pro headlines, there are several stocks whose turnaround story have been under the watchful eye of sell-side analysts. The Headline: "Chardan Analyst Believe iPass Inc. (NASDAQ: IPAS)' Turnaround Strategy Is Working - also upgraded the...